Global Phase-III trial of (Ad5-nCOV) Covid19 vaccine making steady progress in Pakistan

Print

Global Phase-III trial of (Ad5-nCOV) 
Covid19 vaccine making steady
progress in Pakistan
Center at UHS working under the supervision 
of Prof. Javed Akram has already vaccinated 
over three thousand volunteers

LAHORE: Global Phase-III Trial of Recombinant Novel Coronavirus vaccine (Adenovirus Type-5 Vector Add5-nCov) being conducted in Pakistan at five sites are making steady progress. These five centers are University of Health Sciences at Lahore, Shifa International Hospital Islamabad, Shaukat Khanum Cancer Hospital, Indus Hospital and Aga Khan University Hospital at Karachi. The Centre functioning at UHS Lahore under the supervision of Prof. Javed Akram who is the Principal Site Investigator at UHS has already successfully completed vaccination of over three thousand volunteers.

Global Principal investigators of the study include Dr. Scott Halperin and Dr. Joanne Langley from Canadian Center for vaccinology, Dallhousie, University, Canada, and Fengcai Zhu from Jiangsu Provincial Center for Disease Control and Prevention, China.

The trial bearing Protocol Number CS-CTP-AD5NCOV-III is funded by CanSino Biologics Inc. The sponsors of the trial are Beijing Institute of Biotechnology, China and CanSino Biologics Inc. of China while the local sponsor are AJM Pharma Ltd. All the ethical guidelines for such research trials are being strictly followed. The volunteers before getting a shot of vaccine are examined, proper medical history is taken, all the documents are prepared and the consent Form is signed by all the volunteers. All the records are being computerized. Dr. Shah Noor Public Health specialist is present on the site at UHS Center supervising the work and the whole staff involved in this trial. The site selected is the UHS Guest House in the basement while four rooms on First Floor are also reserved for this Trial where some staff members are working.

It may be mentioned here that the common symptoms of COVID19 are fever, tiredness, dry cough. Some patients may have aches and pains, nasal congestion, sore throat or diarrhoea. These symptoms are usually mild. However, elderly people with wakened immune systems and people with underlying medical problems like lung problems, heart problems or diabetes have a much higher risk of developing serious complications. Researchers all over the world are studying the virus and its effects and working on ways to fight it which includes potential vaccines. The sponsors are targeting total of thirty to forty thousand adults between the ages eighteen years or older who will take part in this study at fifty sites worldwide. This is blinded randomized study. All the volunteers taking part in this study are given detailed instructions and also provided printed information which also highlight the Rights of the research subjects.

© Professional Medical Publications. All rights reserved.